Predictors of Functional Remission in Discharged Patients With Schizophrenia After Long-term Drug Discontinuation
NCT05667961 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 480
Last updated 2025-04-25
Summary
Study objectives:
1. Describe the characteristics of discharged patients with schizophrenia achieving functional remission after drug discontinuation.
2. Establish a prediction model of patients with schizophrenia having good prognosis after drug discontinuation.
Conditions
Sponsors & Collaborators
- collaborator INDUSTRY
-
Shanghai Mental Health Center
lead OTHER
Principal Investigators
-
Dengtang Liu · Shanghai Mental Health Center
Eligibility
- Min Age
- 18 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-09-15
- Primary Completion
- 2025-01-31
- Completion
- 2025-03-31
Countries
- China
Study Locations
More Related Trials
-
Relapse Prevention in First Episode Schizophrenia: a 5 Year Trial
NCT01936220 ·Status: UNKNOWN ·Phase: NA
-
Mental Health During the Whole Life Cycle of Community Patients with Schizophrenia
NCT05159349 ·Status: RECRUITING
-
Evaluating Pharmacogenomics-Based Pharmacotherapy in Real-World Settings for Schizophrenia
NCT06700967 ·Status: NOT_YET_RECRUITING
-
Observational Study to Evaluate Efficacy and Remission Status for Schizophrenia Patients Under Atypical Treatment
NCT00809731 ·Status: COMPLETED
-
Efficacy and Safety of Psychopharmacotherapy in Patients With Schizophrenia or Bipolar Disorders
NCT00330226 ·Status: UNKNOWN
-
Dual Modulation of Sigma-1 and NMDA Receptors in the Treatment of Schizophrenia
NCT06574360 ·Status: RECRUITING ·Phase: PHASE2
-
Oculomotor and Spatial Cognition Deficits in Schizophrenia
NCT00931996 ·Status: TERMINATED ·Phase: NA
-
Genes Polymorphisms and Metabolic Effects of the Second Generation Antipsychotic Drugs in Patients With Schizophrenia
NCT02964923 ·Status: UNKNOWN
-
The Establishment of the Early Intervention Program for Patients With Schizophrenia
NCT00172770 ·Status: UNKNOWN
-
Antipsychotic Induced Structural and Functional Brain Changes
NCT02435095 ·Status: TERMINATED ·Phase: PHASE4
-
Early Medication Discontinuation and Long-term Clinical Outcome in FEP
NCT01926340 ·Status: COMPLETED
-
Discriminant Validity of the Multiple Errands Test in Schizophrenia
NCT02782091 ·Status: COMPLETED ·Phase: NA
-
Functional Relevance of Dopamine Receptors in Healthy Controls and Patients With Schizophrenia: Characterization Through [11C]NNC-112 and [18F]Fallypride Positron Emission Tomography
NCT00942981 ·Status: COMPLETED
-
Study on Abnormal Dopamine Synthesis and Connectivity According to the Antipsychotic Treatment Response in Schizophrenia
NCT02248987 ·Status: COMPLETED
-
Social Functioning in Schizophrenia
NCT00814996 ·Status: COMPLETED
-
Serotonin 1A Agonists and Cognition in Schizophrenia
NCT00178971 ·Status: COMPLETED ·Phase: PHASE3
-
Study on Predictiors and Mechanism of Conversion to Psychosis in Individuals at Ultra-high Risk Group
NCT03965598 ·Status: UNKNOWN
-
A Study on the Efficacy of Agomelatine Combined With Antipsychotics to Treat Negative Symptoms in Schizophrenia
NCT05646264 ·Status: UNKNOWN ·Phase: PHASE4
-
Effectiveness of Antipsychotic Combination With Psychosocial Intervention on Outcome of Patients With Schizophrenia
NCT00654576 ·Status: COMPLETED ·Phase: PHASE4
-
Identifying Predictors of Response to Antipsychotics Using a Treatment Algorithm
NCT01016145 ·Status: UNKNOWN ·Phase: PHASE4
-
A Study on Etiological Factors of Schizophrenia
NCT00155636 ·Status: TERMINATED
-
The Effect of a Six Week Intensified Pharmacological Treatment for Schizophrenia Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.
NCT05958875 ·Status: RECRUITING ·Phase: PHASE4
-
"Multimodal Prevention of Psychosis - Investigating Efficacy of N-Acetylcysteine and Psychotherapy in CHR-Patients"
NCT03149107 ·Status: TERMINATED ·Phase: PHASE3
-
Enhancing Motivation in Recent Onset Schizophrenia
NCT01817387 ·Status: TERMINATED ·Phase: NA
-
The Optimal Treatment for Treatment-resistant Schizophrenia
NCT02926976 ·Status: UNKNOWN ·Phase: NA